MOTS-c: A Mitochondrial Peptide That Reads as an Energy Signal

The short version

MOTS-c is a short protein fragment — just 16 amino acids — built from an unusual source: a gene sequence tucked inside the mitochondria, the compartments that generate a cell's usable energy, rather than the main genome in the nucleus. Its best-documented job is acting like a fuel-status messenger: when a cell senses metabolic stress, MOTS-c can travel to the nucleus and switch on genes involved in stress defense and metabolism. In mice, giving MOTS-c improves how muscle handles glucose and can prevent diet-induced weight gain and insulin resistance. Here is the honest catch: essentially none of that comes from a completed human drug trial. The human data on this page are association studies — patterns found in blood samples — not interventional evidence that giving a person MOTS-c does anything at all. This page reports the animal and cell-level mechanism plus the human association data, cited by number, and draws no dosing conclusions.

What it is

MOTS-c is a 16-amino-acid peptide with the sequence MRWQEMGYIFYPRKLR, translated from a short open reading frame within the mitochondrial 12S ribosomal RNA gene (MT-RNR1) — part of the mitochondrion's own small, separate genome, not the cell's nuclear DNA. It belongs to a small family known as mitochondrial-derived peptides (MDPs), molecules whose existence was recognized only once researchers started looking for coding sequences hiding inside supposedly non-coding mitochondrial RNA. The sequence is highly conserved across mammalian species, generally a sign that a molecule is doing something biologically important enough that evolution keeps it intact.

How it works

MOTS-c's best-characterized action is inhibiting the folate cycle and de novo purine biosynthesis. Blocking that pathway raises intracellular AICAR, which activates AMP-activated protein kinase (AMPK) — the enzyme that functions as a cell's low-fuel alarm, switching metabolism from building things to breaking things down for energy when fuel is scarce. In skeletal muscle, this translates into improved glucose uptake and insulin sensitivity in animal models ^[11].

Under metabolic stress, MOTS-c also does something unusual for a mitochondrial product: it translocates out of the mitochondrion and into the nucleus, where it regulates nuclear gene expression in an AMPK-dependent manner, including antioxidant-response-element genes via the NRF2 transcription factor — the first demonstrated case of a mitochondrial-encoded peptide sending a retrograde signal back to the genome that houses most of the cell's DNA ^[10]. A 2024 study added a more direct mechanistic anchor: MOTS-c physically binds and activates casein kinase 2 (CK2) in cell-free systems, with tissue-specific effects — activating CK2 in muscle while suppressing it in fat — that the same study ties to preventing muscle atrophy and boosting muscle glucose uptake in mice ^[6].

What the research shows

The clearest mechanistic anchor is the 2024 discovery that MOTS-c directly binds and activates casein kinase 2 (CK2) in cell-free assays — identifying CK2 as a direct molecular target for the first time, with tissue-specific modulation (activating CK2 in muscle, suppressing it in fat) that prevented skeletal-muscle atrophy and enhanced muscle glucose uptake in mice across young, aged, high-fat-diet, and immobilized models ^[6].

The founding 2015 paper that first identified MOTS-c showed it inhibits the folate cycle and de novo purine synthesis to activate AMPK, and that treated mice were protected against age-dependent and high-fat-diet-induced insulin resistance and diet-induced obesity, with skeletal muscle as the primary target organ ^[11]. A 2018 follow-up demonstrated the nuclear-translocation mechanism described above ^[10]. In 2021, researchers showed exercise induces endogenous MOTS-c expression, and that exogenous MOTS-c significantly enhanced physical performance across young, middle-aged, and old mice — including a statistically striking increase in treadmill running capacity in aged mice (22-23.5 months) at P=0.000002, alongside improved grip strength and gait ^[9]. Most recently, a 2025 rat study of type-2 diabetes found MOTS-c treatment increased oxidative-phosphorylation respiration in cardiac mitochondria, alongside lower fasting glucose and reduced left-ventricular hypertrophy ^[12].

The strongest human data point is observational, not interventional: a prospective multicenter cohort of 94 chronic hemodialysis patients, followed for a median of 26.5 months, found circulating MOTS-c was independently associated with a composite of all-cause mortality and non-fatal cardiovascular events (Cox HR 1.004, p=0.05), and adding it to a risk model improved discrimination from an ROC AUC of 0.727 to 0.743 ^[7]. A 2023 review consolidates the full mechanism and indication-spanning evidence base ^[8].

Reported effects, cautions & safety

MOTS-c has no community-reported anecdote set on this page, and that omission is deliberate rather than an oversight: unlike the other three compounds here, there is no completed human interventional trial of exogenous MOTS-c to generate reported effects from, so this desk will not manufacture a benefits-and-side-effects list where none is documented.

What the literature does support is a set of cited limitations. Every claim about exogenous MOTS-c improving metabolism, exercise performance, or aging comes from cell or animal studies — predominantly mice and rats — not human interventional trials; the human data that exists is the observational hemodialysis-cohort association described above ^[7]. There is no validated human pharmacokinetic profile: no published, measured human half-life, bioavailability, or dose-response curve exists, and the rodent dose range used in published studies cannot be responsibly extrapolated to a human dose. MOTS-c is sold only as a research chemical, unregulated as a pharmaceutical, with purity and identity varying by supplier. Anti-doping authorities, including USADA and WADA, treat MOTS-c as a prohibited substance in elite sport under hormone-and-metabolic-modulator categories. A pro-diabetogenic mitochondrial DNA variant and ancestry-dependent exercise responses documented in the literature suggest MOTS-c's effects are not uniform across populations — one more reason the animal-model numbers above should not be read as a human prescription.

Where it fits in cellular energy and metabolism

MOTS-c is the tightest fit for this site's cellular-energy frame, and it is the lead compound for exactly that reason. It is encoded inside mitochondrial DNA, its best-established mechanism (folate-cycle inhibition activating AMPK) is a direct read on cellular fuel status, and its 2024 CK2-binding data gives it a specific, non-speculative molecular target ^[6]. Where tirzepatide and retatrutide change energy metabolism from the outside — engaging hormone receptors that regulate insulin, glucagon, and appetite — MOTS-c is proposed to work as an endogenous signal the mitochondrion sends when it senses it is running low on fuel. GHK-Cu, by contrast, sits at the frame's edge, with its strongest evidence in tissue repair rather than metabolism. The honest asterisk on MOTS-c's lead position: its mechanism is the best fit, but its human evidence is the thinnest of the four. See the comparison page for how all four stack up.